CTR20262376 Telisotuzumab adizutecan Metastatic Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready landscape. This focused report examines CTR20262376—一项在一线转移性胰腺导管腺癌成人受试者中评估静脉注射（IV）Telisotuzumab Adizutecan与氟尿嘧啶、亚叶酸和奥沙利铂（FOLFOX）联合治疗相比标准治疗的研究—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262376 is a hot trial to watch
Metastatic Pancreatic Ductal Adenocarcinoma is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. CTR20262376 is notable because it evaluates Telisotuzumab adizutecan in a Phase 2 design while II期和III期：盲态独立中心审查委员会（BICR）根据实体瘤疗效评价标准（RECIST）v1.1评估的总体缓解（OR） serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262376 |
| Official title | 一项在一线转移性胰腺导管腺癌成人受试者中评估静脉注射（IV）Telisotuzumab Adizutecan与氟尿嘧啶、亚叶酸和奥沙利铂（FOLFOX）联合治疗相比标准治疗的研究 |
| Phase / status | Phase 2 / 进行中 （尚未招募） |
| Intervention | Telisotuzumab adizutecan, Telisotuzumab Adizutecan, 氟尿嘧啶, 亚叶酸, 奥沙利铂, 伊立替康 |
| Sponsor | BSP Pharmaceuticals SpA, AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie, Inc. |
| Collaborators | Not reported |
| Geography | United States, Taiwan Province, China |
| Enrollment | 50 |
| Primary endpoint | II期和III期：盲态独立中心审查委员会（BICR）根据实体瘤疗效评价标准（RECIST）v1.1评估的总体缓解（OR） |
| Endpoint time frame | 直至研究完成，约6年 |
| Primary completion / readout proxy | 2026-06-29 |
Design and endpoint interpretation
The phase label is only the starting point. Allocation is 随机化, masking is 开放, and the intervention model is 平行分组. Planned enrollment of 50 participants across United States, Taiwan Province, China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary: II期和III期：盲态独立中心审查委员会（BICR）根据实体瘤疗效评价标准（RECIST）v1.1评估的总体缓解（OR） (直至研究完成，约6年)
- Primary: III期：总生存期（OS） (直至研究完成，约6年)
- Secondary: II期和III期：BICR根据RECIST v1.1评估的无进展生存期（PFS） (直至研究完成，约6年)
- Secondary: II期和III期：BICR根据RECIST v1.1评估的缓解持续时间（DoR） (直至研究完成，约6年)
- Secondary: II期和III期：BICR根据RECIST v1.1评估的临床获益（CB） (直至研究完成，约6年)
Benchmark readouts in the surrounding field
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
- A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)
- A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (Phase 2): Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -0.4 percent change (Standard Error, 0.91); Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -9.4 percent change (Standard Error, 1.60)
These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.
Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Telisotuzumab adizutecan (Phase 3; Top I x c-Met)
Company & Deal Intelligence context: BSP Pharmaceuticals SpA — Italy — http://www.bsppharmaceuticals.com; AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd. — China; AbbVie, Inc. — United States — https://www.abbvie.com
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.
Bottom line
CTR20262376 is a focused lens on Metastatic Pancreatic Ductal Adenocarcinoma development. Its value will be determined by whether Telisotuzumab adizutecan can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
